
    
      Phase 2b/3, randomized, double-blind, multicenter, placebo-controlled study evaluating the
      safety, efficacy and pharmacokinetics (PK) of pagibaximab (100 mg/kg/dose) in comparison to
      placebo for the prevention of staphylococcal sepsis in VLBW infants (600 -1200 grams).
      Subjects monitored for treatment related adverse events and tolerability to infusion of study
      drug. Neonatal sepsis will be assessed in the presence of clinical signs and symptoms and one
      blood culture positive for S. aureus or two blood cultures positive for Coagulase Negative
      Staphylococci (CoNS). The study period will be 35 days after the first dose or until, death,
      discharge, or transfer, whichever occurs first.
    
  